Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial (Q40683161)

22 September 2017

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial (English)

1 reference

22 September 2017

phase II clinical trial

0 references

1 reference

15

Ulf Müller-Ladner

1 reference

22 September 2017

13

Gabriela Riemekasten

1 reference

22 September 2017

Janet E Pope

12

0 references

author name string

Dinesh Khanna

1

1 reference

22 September 2017

Christopher P Denton

2

1 reference

22 September 2017

Angelika Jahreis

3

1 reference

22 September 2017

Jacob M van Laar

4

1 reference

22 September 2017

Tracy M Frech

5

1 reference

22 September 2017

Marina E Anderson

6

1 reference

22 September 2017

Murray Baron

7

1 reference

22 September 2017

Lorinda Chung

8

1 reference

22 September 2017

Gerhard Fierlbeck

9

1 reference

22 September 2017

Santhanam Lakshminarayanan

10

1 reference

22 September 2017

Yannick Allanore

11

1 reference

22 September 2017

Virginia Steen

14

1 reference

22 September 2017

Robert Lafyatis

16

1 reference

22 September 2017

Giuseppina Stifano

17

1 reference

22 September 2017

Helen Spotswood

18

1 reference

22 September 2017

Haiyin Chen-Harris

19

1 reference

22 September 2017

Sebastian Dziadek

20

1 reference

22 September 2017

Alyssa Morimoto

21

1 reference

22 September 2017

Thierry Sornasse

22

1 reference

22 September 2017

Jeffrey Siegel

23

1 reference

22 September 2017

Daniel E Furst

24

1 reference

22 September 2017

language of work or name

English

0 references

publication date

5 May 2016

1 reference

22 September 2017

1 reference

22 September 2017

387

1 reference

22 September 2017

10038

1 reference

22 September 2017

2630-2640

1 reference

Epidemiology of systemic sclerosis.

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Interleukin-6: a new therapeutic target in systemic sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

The cytokine language of monocytes and macrophages in systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Novel insights in the regulation of CCL18 secretion by monocytes and dendritic cells via cytokines, toll-like receptors and rheumatoid synovial fluid

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Biological roles of lysophosphatidic acid signaling through its production by autotaxin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Increased serum COMP predicts mortality in SSc: results from a longitudinal study of interstitial lung disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Serum CC chemokine ligand-18 predicts lung disease worsening in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Improvement in skin thickening in systemic sclerosis associated with improved survival

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Severe organ involvement in systemic sclerosis with diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Mortality and survival in systemic sclerosis: systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Old medications and new targeted therapies in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2816%2900232-4

7 January 2021

10.1016/S0140-6736(16)00232-4

Identifiers

DOI

1 reference

22 September 2017

1 reference